Status:
COMPLETED
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera
Lead Sponsor:
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Conditions:
Adherence, Patient
Adherence, Treatment
Eligibility:
All Genders
18+ years
Brief Summary
The prospective multicenter observational cohort study will be offered consecutively to any patient with primary or secondary myelofibrosis or with Polycythemia Vera who has initiated therapy with rux...
Detailed Description
The prospective multicenter observational cohort study will be offered consecutively to any patient with primary or secondary myelofibrosis or with Polycythemia Vera who has initiated therapy with rux...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Patients diagnosed with Primary Myelofibrosis or secondary to Essential Thrombocythemia/Polycythemia Vera or diagnosed with Polycythemia Vera who are in the treatment with ruxolitinib therapy in accordance with normal clinical practice
- Obtaining informed consent for data collection and processing
- The Patient must come to the in-person visit at least once, an occasion on which informed consent to 'study membership will be offered
Exclusion
- None
Key Trial Info
Start Date :
January 18 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2023
Estimated Enrollment :
189 Patients enrolled
Trial Details
Trial ID
NCT06078319
Start Date
January 18 2021
End Date
June 30 2023
Last Update
October 12 2023
Active Locations (28)
Enter a location and click search to find clinical trials sorted by distance.
1
Azienda Ospedaliera Annunziata
Cosenza, Calabria, Italy, 87100
2
Grande Ospedale Metropolitano "Bianchi Melacrino Morelli"
Reggio Calabria, Calabria, Italy, 89124
3
Università degli Studi di Napoli Federico II - U.O.C. di Ematologia e Trapianti di midollo
Napoli, Campania, Italy, 80131
4
IRCCS Policlinico Sant'Orsola
Bologna, Emilia-Romagna, Italy, 40138